Clinical trials: M-protein
Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism
Stable Isotopes- Adults With Obesity
In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes.
- Conditions
- Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
- Trial name
- Si-OBA (NCT07020741)
- Testing
- Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Urbana-Champaign
COVID-19 Infection
A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
This is a phase II randomised, multicentre, prospective, open label clinical trial. The trial aims to recruit patients who test positive for COVID-19 who have mild symptoms and therefore can treat their symptoms in the community.
- Trial name
- SPIKE-1 (NCT04455815)
- Testing
- Camostat
- Where
- 9 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Cancer Research UK
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
SARS-CoV-2 Infection, COVID-19
A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults
This is a study to evaluate the effectiveness and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in a minimum of approximately 2,960 to a maximum of approximately 4,164…
- Trial name
- NCT04533399
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant
- Where
- 14 sites in South Africa
- Volunteers
- 4,422 people, healthy volunteers welcome
- Sponsor
- Novavax
Multiple Myeloma
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy
This is an international,multicenter, prospective, open, double randomised and controlled phase III study to compare the therapeutic efficacy of tandem high dose Melphalan versus triple intermediate dose Melpahaln in…
- Trial name
- NCT00205764
- Testing
- Melphalan
- Where
- Austria
- Volunteers
- 212 people
- Sponsor
- Austrian Forum Against Cancer
Proliferative Glomerulonephritis With Monoclonal IgG Deposits
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
- Trial name
- NCT05654506
- Testing
- Daratumumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
SARS-CoV-2
A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM…
- Trial name
- NCT05181709
- Testing
- Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sean Liu
Malaria, Malaria,Falciparum
A Study to Compare Two Dosing Regimens for a New Malaria Vaccine
Malaria is a major public health problem. There were around 240 million cases of malaria and 627,000 deaths worldwide in 2020. Most of the deaths are in children under five living in Africa.
- Conditions
- Malaria, Malaria,Falciparum, Protozoan Infections, Parasitic Disease
- Trial name
- NCT06141057
- Testing
- Matrix M with RH5.1
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Myeloma
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
The goal of this clinical research study is to find the highest tolerable dose of Siltuximab that can be given in combination with Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone to patients with MM.
- Trial name
- NCT01531998
- Testing
- Lenalidomide, Bortezomib, Siltuximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
COVID-19 Vaccine, Safety Issues
ChulaCov19 Vaccine in Healthy Adults
This study will be conducted in 2 phases. Phase 1 of this study will be a single-centre, open label, dose escalation first in human (FIH) study conducted in 2 groups of healthy participants.
- Trial name
- NCT04566276
- Testing
- ChulaCov19 vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Multiple Myeloma
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine whether the combination of bevacizumab and bortezomib have increased efficacy in the treatment of relapsed/ refractory multiple myeloma.
- Trial name
- NCT00464178
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Immunoglobulin Light-Chain Amyloidosis
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Research Objective:At present, there is no standard therapeutic regimen for monoclonal immunoglobulin light chain (AL) amyloidosis in the world.
- Trial name
- NCT04612582
- Testing
- Thalidomide, Cyclophosphamide
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Guangdong Provincial People's Hospital
Waldenstrom Macroglobulinemia
Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)
Background: Waldenstrom macroglobulinemia (WM) is a type of blood cancer. It causes the blood to get thicker, which slows circulation and makes it harder to carry oxygen and other substances around the body.
- Trial name
- NCT07882173
- Testing
- epcoritamab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)